logo
  

Sandoz To Acquire Antifungal Agent Mycamine From Astellas Pharma

Sandoz said it has entered into an agreement to acquire worldwide product rights for systemic antifungal agent Mycamine from Astellas Pharma Inc. (ALPMY,ALPMY). Closing is anticipated in the course of first half of 2023.

Sandoz stated that addition of Mycamine will support its global program to combat antimicrobial resistance by targeted use of the most appropriate therapies.

Astellas said it will receive $62.5 million - $75 million upfront payament, depending on the date of the closing of the transaction, and potential sales-based milestone payments.

Astellas reported Mycamine sales of US$135 million for the year ending March 31, 2022.

Mycamine is indicated for treatment of invasive candidiasis and espophageal candidiasis, which are currently both on the rise with a higher occurrence of associated hospital outbreaks, as well as prevention of candida and aspergillus infections in patients undergoing hematopoietic stem cell transplantation.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT